IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Researchers test if extra year of kidney drug boosts protection
Disease control Recruiting nowThis study is for adults with IgA nephropathy, a kidney disease, who have already completed a standard 9-month course of the drug TARPEYO. It aims to see if continuing the treatment for another 15 months at a lower dose is safe and provides better long-term control of the disease…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE4 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo aims to protect kidneys from scarring
Disease control Recruiting nowThis study is testing whether combining two existing medicines—budesonide and ambrisentan—can help people with IgA nephropathy, a kidney disease. Researchers want to see if this combination reduces protein in urine and slows the decline of kidney function over 36 weeks. The study…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
First human test for new kidney disease drug begins
Disease control Recruiting nowThis is an early-stage study to check if a new drug called BHV-1400 is safe for people with IgA nephropathy, a disease that damages the kidneys. The study will enroll 20 adults who have had the disease confirmed by a kidney biopsy. Researchers will closely monitor participants fo…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Last hope kidney treatment now available outside trials
Disease control AVAILABLEThis program provides access to an experimental drug called atrasentan for people with IgA nephropathy, a serious kidney disease. It's designed for patients who have no other treatment options and cannot join regular clinical trials. Doctors can request the medication for eligibl…
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC